Nicholas David Kindon

This inventor holds 17 USPTO granted patents, plus 2 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Astrazeneca Ab, Astra Pharmaceuticals Limited, Astra Zeneca U.k. Limited. Active years: 1998-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas David Kindon. Retrieved from https://idiyas.com/inventor/nicholas-david-kindon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17

% Patents Active = 52.9

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 3.3

ph-index = 7

Forward Citations = 147(Granted Patents)

Location History:

Ibstock, GB (1998 - 1999)
Leics, GB (1999)
Ashby de la Zouch, GB (2000 - 2001)
Loughborough, GB (2000 - 2012)
Cheshire, GB (2013)
Leicestershire, GB (2003 - 2014)

Company Filing History:

Astra Pharmaceuticals Limited

patents

4 out of 110

Astra Zeneca U.k. Limited

patents

4. 3 out of 7

Pulmagen Therapeutics (Synergy) Limited

patents

where one patent can have more than one assignee

Years Active: 1998-2014

Loading Chart...

Areas of Expertise:

P2X7 Receptor Antagonists

Pyrazinyl-Phenylsulphonamides

Uracil Compounds

Pyrimidin Derivatives

N-Alkyl ATP Analogues

Chemokine Receptor Modulators

Inflammatory Diseases

Cardiovascular Treatment

Medicinal Chemistry

Therapeutic Agents

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8629271 - Compounds (2014-01-14),

2. 8476265 - Compounds-801 (2013-07-02),

3. 8455483 - Compounds—801 (2013-06-04),

4. 8148373 - Compounds (2012-04-03),

5. 7662825 - N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases (2010-02-16),

6. 7410972 - Compounds (2008-08-12),

7. 6946478 - Compounds (2005-09-20),

8. 6812226 - P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease (2004-11-02),

9. 6562825 - Piperazine derivatives as modulators of chemokine receptor activity (2003-05-13),

10. 6518286 - Compounds (2003-02-11),

11. 6218376 - Uracil compounds as P2-purinoreceptor 7-transmembrane G-protein coupled receptor antagonists (2001-04-17),

12. 6200981 - Pyrimidin derivatives (2001-03-13),

13. 6162808 - Compounds (2000-12-19),

14. 6107297 - 2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent (2000-08-22),

15. 5985849 - Phosphate compounds and their use as medicaments (1999-11-16),

Title: The Innovations of Nicholas David Kindon

Introduction: Nicholas David Kindon, an accomplished inventor based in Leicestershire, GB, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 17 patents. His work primarily focuses on the development of innovative compounds that hold promise in therapeutic applications.

Latest Patents: Among his latest patents are groundbreaking inventions related to spirocyclic amide derivatives. The present invention relates to these derivatives, including pharmaceutically acceptable salts and methods for their preparation. These compounds have been designed for use in therapy, showcasing Kindon's commitment to advancing medicine. Another noteworthy patent is Compounds-801, which describes spirocyclic amide derivatives that include a beta-adrenoceptor binding group, along with processes for their preparation and pharmaceutical compositions. These inventions highlight his innovative approach to developing effective therapeutic solutions.

Career Highlights: Throughout his career, Nicholas has held positions in esteemed companies such as AstraZeneca and Astra Pharmaceuticals Limited. His work in these organizations has been instrumental in the development of pharmaceutical innovations, contributing to the advancement of medical science.

Collaborations: Nicholas's innovative journey has been supported by talented colleagues, including Stephen Thom and Bryan Glyn Roberts. Their collaborations have strengthened his ability to pioneer new inventions that push the boundaries of pharmaceutical research.

Conclusion: Nicholas David Kindon stands out as a notable inventor whose contributions to the field of pharmaceuticals are marked by his extensive patent portfolio and collaborative efforts. His inventions not only reflect his dedication to innovation but also hold the potential for significant therapeutic advancements in healthcare.

Profile summary based on public USPTO records.